Susquehanna International Group Ltd. Enlivex Therapeutics Ltd. Transaction History

Susquehanna International Group Ltd.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.46 - $2.97 $4,036 - $8,212	-2,765 Reduced 18.32%	12,326 $19,000
Q2 2023 Aug 11, 2023	SELL	$2.51 - $3.71 $6,965 - $10,295	-2,775 Reduced 15.53%	15,091 $39,000
Q1 2023 May 16, 2023	SELL	$3.41 - $4.55 $3,481 - $4,645	-1,021 Reduced 5.41%	17,866 $65,000
Q4 2022 Feb 14, 2023	SELL	$3.74 - $4.81 $5,280 - $6,791	-1,412 Reduced 6.96%	18,887 $74,000
Q3 2022 Nov 14, 2022	SELL	$4.11 - $5.87 $6,999 - $9,996	-1,703 Reduced 7.74%	20,299 $85,000
Q2 2022 Aug 15, 2022	SELL	$3.81 - $8.64 $1,790 - $4,060	-470 Reduced 2.09%	22,002 $98,000
Q1 2022 May 16, 2022	BUY	$4.92 - $6.66 $110,562 - $149,663	22,472 New	22,472 $126,000

2.58M

20.8K

Ticker ENLV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,403,200
Market Cap $23.2M
Description
Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2...

Get notified when there are updates to the investment portfolio of Susquehanna International Group Ltd., based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group Ltd. with notifications on news.